Literature DB >> 18360288

Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

Julie B Dumond1, Y Sunila Reddy, Luigi Troiani, Jose F Rodriguez, Arlene S Bridges, Susan A Fiscus, Geoffrey J Yuen, Myron S Cohen, Angela D M Kashuba.   

Abstract

OBJECTIVES: To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC) concentrations in blood and semen of HIV-1-infected men.
DESIGN: : Nonblind, single-center, open-label pharmacokinetic (PK) study in 14 subjects receiving ZDV plus 3TC.
METHODS: Paired blood and semen samples were obtained during 1 intensive visit and 3 single time point visits over 2 weeks. Extracellular ZDV and 3TC concentrations were measured in blood plasma (BP) and seminal plasma (SP), and intracellular ZDV and 3TC triphosphate (TP) concentrations were measured in isolated mononuclear cells using validated methods. HIV-1 RNA was measured in blood and semen. PK parameters were estimated using noncompartmental analysis.
RESULTS: Median (interquartile range [IQR]) SP/BP area under the time-concentration curve over the 12-hour dosing interval (AUC0-12h) ratios for ZDV and 3TC were 2.28 (1.48 to 2.97) and 6.67 (4.10 to 9.14), respectively, whereas individual SP/BP concentration ratios ranged from 1.9 to 91.4. Intracellular median (IQR) SP/BP AUC0-12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9. HIV-1 RNA was undetectable in both compartments.
CONCLUSIONS: ZDV and 3TC SP exposures are 2- to 6-fold greater than BP exposures. Seminal ZDV-TP exposures are approximately 40% of those found in peripheral blood mononuclear cells (PBMCs), whereas 3TC-TP exposures are similar to PBMC exposures. PK variability makes individual SP/BP ratios a suboptimal surrogate for genital tract exposure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18360288      PMCID: PMC2862269          DOI: 10.1097/QAI.0b013e31816de21e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  53 in total

1.  Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

Authors:  R M van Praag; R P van Heeswijk; S Jurriaans; J M Lange; R M Hoetelmans; J M Prins
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

2.  The NIH condom report: the glass is 90% full.

Authors:  W Cates
Journal:  Fam Plann Perspect       Date:  2001 Sep-Oct

3.  Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection.

Authors:  P L Anderson; S E Noormohamed; K Henry; R C Brundage; H H Balfour; C V Fletcher
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

4.  Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

Authors:  Naumann I Chaudry; Joseph J Eron; Odin J Naderer; Arlene S Pereira; M B Wire; Susan A Fiscus; Angela D M Kashuba
Journal:  Clin Infect Dis       Date:  2002-08-23       Impact factor: 9.079

5.  The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis.

Authors:  S Tariq Sadiq; Stephen Taylor; Steve Kaye; Julie Bennett; Ruth Johnstone; Patrick Byrne; Andrew J Copas; Susan M Drake; Deenan Pillay; Ian Weller
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

6.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.

Authors:  H Chakraborty; P K Sen; R W Helms; P L Vernazza; S A Fiscus; J J Eron; B K Patterson; R W Coombs; J N Krieger; M S Cohen
Journal:  AIDS       Date:  2001-03-30       Impact factor: 4.177

7.  Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry.

Authors:  A S Pereira; K B Kenney; M S Cohen; J E Hall; J J Eron; R R Tidwell; J A Dunn
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-05-26

8.  Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.

Authors:  C V Fletcher; S P Kawle; T N Kakuda; P L Anderson; D Weller; L R Bushman; R C Brundage; R P Remmel
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

9.  Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.

Authors:  J F Rodriguez; J L Rodriguez; J Santana; H García; O Rosario
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

Authors:  Arlene S Pereira; Laura M Smeaton; John G Gerber; Edward P Acosta; Sally Snyder; Susan A Fiscus; Richard R Tidwell; Roy M Gulick; Robert L Murphy; Joseph J Eron
Journal:  J Infect Dis       Date:  2002-06-26       Impact factor: 5.226

View more
  22 in total

1.  Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Authors:  Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 2.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 3.  Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.

Authors:  Oluwatosin O Ogedengbe; Edwin C S Naidu; Onyemaechi O Azu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

4.  Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Authors:  C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 5.  HIV-1 treatment as prevention: the good, the bad, and the challenges.

Authors:  Kumi Smith; Kimberly A Powers; Angela D M Kashuba; Myron S Cohen
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

6.  Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?

Authors:  Floris Fauchet; Jean-Marc Treluyer; Elodie Valade; Sihem Benaboud; Emmanuelle Pannier; Ghislaine Firtion; Frantz Foissac; Naim Bouazza; Saik Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

7.  Xenobiotic transporter expression along the male genital tract.

Authors:  David M Klein; Stephen H Wright; Nathan J Cherrington
Journal:  Reprod Toxicol       Date:  2014-05-09       Impact factor: 3.143

Review 8.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

9.  Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Authors:  Elodie Valade; Jean-Marc Tréluyer; Silvia M Illamola; Naïm Bouazza; Frantz Foissac; Maïlys De Sousa Mendes; Gabrielle Lui; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Déborah Hirt; Saïk Urien; Jade Ghosn
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.

Authors:  Christophe Pasquier; Karine Sauné; Stéphanie Raymond; Nathalie Moinard; Myriam Daudin; Louis Bujan; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2009-07-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.